EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort

Sveinung Wergeland Sørbye iD, Bente Marie Falang, Mona Antonsen, Elin Richardsen iD

Pathogens · 17.07.2026 · 15 (7) · 747

DOI: 10.3390/pathogens15070747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 17.07.2026. Verfasst von Sveinung Wergeland Sørbye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, University Hospital of North Norway, 9006 Tromsø, Norway. Hauptthemen laut MEDLINE: Papillomavirus Infections, RNA, Messenger, Oncogene Proteins, Viral, Uterine Cervical Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HPV DNA-positive women with ASC-US/LSIL cytology constitute a heterogeneous triage group. We evaluated genotype-specific HPV E6/E7 mRNA testing with PreTect HPV-Proofer’7 in a population-based cohort from Tromsø and compared the findings descriptively with a previously published cohort from Bodø. This retrospective quality-assurance study included 1006 HPV DNA-positive women with ASC-US/LSIL cytology screened between 2019 and 2024, with linkage to regional pathology records through 31 December 2025. The assay detects E6/E7 mRNA from HPV16, 18, 31, 33, 45, 52, and 58. ASC-US/LSIL accounted for 42.5% of linked HPV DNA-positive women in Tromsø compared with 22.3% in Bodø. Among the mRNA-tested ASC-US/LSIL cohorts, mRNA positivity was similar (40.8% vs. 44.6%). In Tromsø, CIN2+ was recorded in 26.1% of mRNA-positive and 7.9% of mRNA-negative women (RR 3.31, 95% CI 2.41–4.55), whereas CIN3+ was recorded in 3.9% and 1.0%, respectively (RR 3.88, 95% CI 1.53–9.82). For CIN2+, sensitivity was 69.5%, specificity 64.4%, PPV 26.1%, and NPV 92.1%. Among HPV16/18 DNA-positive women, CIN2+ risk was 42.7% in mRNA-positive and 13.4% in mRNA-negative women. Simulated mRNA-guided referral reduced immediate colposcopy referrals by 59.2%. Genotype-specific mRNA testing provided clinically relevant risk stratification, with directionally similar patterns being observed in the Tromsø and Bodø cohorts; however, mRNA-negative women require structured surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsRNA, MessengerOncogene Proteins, ViralUterine Cervical NeoplasmsHuman Papillomavirus VirusesPapillomaviridaeSquamous Intraepithelial Lesions of the CervixHumansFemaleGenotypeRetrospective StudiesTriageAdultMiddle AgedDNA, ViralRNA, ViralAtypical Squamous Cells of the CervixNorwayUterine Cervical DysplasiaAgedRisk AssessmentEarly Detection of Cancer

Stichwörter der Autor:innen

ASC-USCIN2+CIN3+HPV DNAHPV E6/E7 mRNALSILPreTect HPV-Proofer’7cervical cancer screeningcolposcopy referralextended genotypingmolecular triage

Substanzen

RNA, MessengerOncogene Proteins, ViralDNA, ViralRNA, Viral

Autor:innen und Institutionen

  • Department of Clinical Pathology, University Hospital of North Norway, 9006 Tromsø, Norway.
  • PreTect AS, 3490 Asker, Norway.

ORCID-Profile: Sveinung Wergeland Sørbye, Elin Richardsen

Zitieren

APA

Sørbye, S. W., Falang, B. M., Antonsen, M., & Richardsen, E. (2026). Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort. Pathogens, 15(7), 747. https://doi.org/10.3390/pathogens15070747

Vancouver

Sørbye SW, Falang BM, Antonsen M, Richardsen E. Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort. Pathogens. 2026;15(7):747. doi:10.3390/pathogens15070747

BibTeX
@article{Srbye2026,
  author = {Sørbye, Sveinung Wergeland and Falang, Bente Marie and Antonsen, Mona and Richardsen, Elin},
  title = {Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {747},
  doi = {10.3390/pathogens15070747}
}
Kostenlos starten →